Download PDF
Semin Thromb Hemost 2011; 37(1): 058-065
DOI: 10.1055/s-0030-1270072
© Thieme Medical Publishers

Hemostatic Disorders in Type 1 Diabetes Mellitus

Giovanni Targher1 , Michel Chonchol2 , Giacomo Zoppini1 , Massimo Franchini3
  • 1Section of Endocrinology, Department of Medicine, University of Verona, Verona, Italy
  • 2Division of Renal Diseases and Hypertension, University of Colorado Denver Health Sciences Center, Aurora, Colorado
  • 3Immunohematology and Transfusion Center, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Parma, Italy
Further Information

Publication History

Publication Date:
19 January 2011 (online)

    Permissions and Reprints

ABSTRACT

This review summarizes current knowledge of the adverse effects of type 1 diabetes mellitus on coagulation and fibrinolysis. Although further larger studies are needed to provide more definitive information, patients with type 1 diabetes exhibit a proinflammatory/procoagulant condition deriving from increased platelet adhesiveness, activation of the coagulation system, and decreased plasma fibrinolytic potential. This review also focuses on recent data from large prospective studies suggesting a strong association between procoagulant imbalance and development of chronic vascular complications in people with type 1 diabetes. It is likely that a greater appreciation of the intimate interactions between endothelial integrity, coagulation and fibrinolytic factors, and platelets in type 1 diabetes will provide a greater understanding of the risk of developing cardiovascular disease and microvascular complications such as nephropathy and retinopathy in this patient population.

KEYWORDS

Type 1 diabetes - coagulation - fibrinolysis - hemostatic disorders

REFERENCES

  • 1 American Diabetes Association . Standards of medical care in diabetes—2010.  Diabetes Care. 2010;  33 ((Suppl 1)) S11-S61
    CrossrefPubMedGoogle Scholar
  • 2 Eckel R H, Wassef M, Chait A et al.. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes.  Circulation. 2002;  105 (18) e138-e143
    CrossrefPubMedGoogle Scholar
  • 3 Franchini M, Targher G, Montagnana M, Lippi G. The metabolic syndrome and the risk of arterial and venous thrombosis.  Thromb Res. 2008;  122 (6) 727-735
    CrossrefPubMedGoogle Scholar
  • 4 Mina A, Favaloro E J, Koutts J. Hemostatic dysfunction associated with endocrine disorders as a major risk factor and cause of human morbidity and mortality: a comprehensive meta-review.  Semin Thromb Hemost. 2007;  33 (8) 798-809
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I, Muggeo M. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome.  Semin Thromb Hemost. 2009;  35 (3) 277-287
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Blann A D, Lip G Y. Endothelial integrity, soluble adhesion molecules and platelet markers in type 1 diabetes mellitus.  Diabet Med. 1998;  15 (8) 634-642
    CrossrefPubMedGoogle Scholar
  • 7 el Khawand C, Jamart J, Donckier J et al.. Hemostasis variables in type I diabetic patients without demonstrable vascular complications.  Diabetes Care. 1993;  16 (8) 1137-1145
    CrossrefPubMedGoogle Scholar
  • 8 Yngen M, Ostenson C G, Hu H, Li N, Hjemdahl P, Wallén N H. Enhanced P-selectin expression and increased soluble CD40 Ligand in patients with type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation.  Diabetologia. 2004;  47 (3) 537-540
    CrossrefPubMedGoogle Scholar
  • 9 Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes.  Diabetes. 2006;  55 (3) 774-779
    CrossrefPubMedGoogle Scholar
  • 10 Davì G, Chiarelli F, Santilli F et al.. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration.  Circulation. 2003;  107 (25) 3199-3203
    CrossrefPubMedGoogle Scholar
  • 11 Hu H, Li N, Yngen M, Ostenson C G, Wallén N H, Hjemdahl P. Enhanced leukocyte-platelet cross-talk in type 1 diabetes mellitus: relationship to microangiopathy.  J Thromb Haemost. 2004;  2 (1) 58-64
    CrossrefPubMedGoogle Scholar
  • 12 Haitas B, Barnes A J, Cederholm-Williams S A, Moore J, Shogry M E, Turner R C. Abnormal endothelial release of fibrinolytic activity and fibronectin in diabetic microangiopathy.  Diabetologia. 1984;  27 (5) 493-496
    CrossrefPubMedGoogle Scholar
  • 13 Carmassi F, Morale M, Puccetti R et al.. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus.  Thromb Res. 1992;  67 (6) 643-654
    CrossrefPubMedGoogle Scholar
  • 14 Reverter J L, Reverter J C, Tàssies D et al.. Thrombomodulin and induced tissue factor expression on monocytes as markers of diabetic microangiopathy: a prospective study on hemostasis and lipoproteins in insulin-dependent diabetes mellitus.  Am J Hematol. 1997;  56 (2) 93-99
    CrossrefPubMedGoogle Scholar
  • 15 Fasching P, Veitl M, Rohac M et al.. Elevated concentrations of circulating adhesion molecules and their association with microvascular complications in insulin-dependent diabetes mellitus.  J Clin Endocrinol Metab. 1996;  81 (12) 4313-4317
    CrossrefPubMedGoogle Scholar
  • 16 Targher G, Bertolini L, Zoppini G, Zenari L, Falezza G. Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in type 1 diabetic patients without clinically manifest macroangiopathy.  Diabet Med. 2005;  22 (8) 999-1004
    CrossrefPubMedGoogle Scholar
  • 17 Smulders R A, Stehouwer C D, Schalkwijk C G, Donker A J, van Hinsbergh V W, TeKoppele J M. Distinct associations of HbA1c and the urinary excretion of pentosidine, an advanced glycosylation end-product, with markers of endothelial function in insulin-dependent diabetes mellitus.  Thromb Haemost. 1998;  80 (1) 52-57
    PubMedGoogle Scholar
  • 18 Giusti C, Schiaffini R, Brufani C, Pantaleo A, Vingolo E M, Gargiulo P. Coagulation pathways and diabetic retinopathy: abnormal modulation in a selected group of insulin dependent diabetic patients.  Br J Ophthalmol. 2000;  84 (6) 591-595
    CrossrefPubMedGoogle Scholar
  • 19 Elhadd T A, Kennedy G, Hill A et al.. Abnormal markers of endothelial cell activation and oxidative stress in children, adolescents and young adults with type 1 diabetes with no clinical vascular disease.  Diabetes Metab Res Rev. 1999;  15 (6) 405-411
    CrossrefPubMedGoogle Scholar
  • 20 Zoppini G, Targher G, Cacciatori V, Guerriero A, Muggeo M. Chronic cigarette smoking is associated with increased plasma circulating intercellular adhesion molecule 1 levels in young type 1 diabetic patients.  Diabetes Care. 1999;  22 (11) 1871-1874
    CrossrefPubMedGoogle Scholar
  • 21 Schalkwijk C G, Poland D C, van Dijk W et al.. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation.  Diabetologia. 1999;  42 (3) 351-357
    CrossrefPubMedGoogle Scholar
  • 22 Rathcke C N, Persson F, Tarnow L, Rossing P, Vestergaard H. YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria.  Diabetes Care. 2009;  32 (2) 323-328
    CrossrefPubMedGoogle Scholar
  • 23 Romano M, Pomilio M, Vigneri S et al.. Endothelial perturbation in children and adolescents with type 1 diabetes: association with markers of the inflammatory reaction.  Diabetes Care. 2001;  24 (9) 1674-1678
    CrossrefPubMedGoogle Scholar
  • 24 Antovic J P, Yngen M, Ostenson C G et al.. Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications.  Blood Coagul Fibrinolysis. 2003;  14 (6) 551-556
    CrossrefPubMedGoogle Scholar
  • 25 Harmanci A, Kandemir N, Dagdelen S et al.. Thrombin-activatable fibrinolysis inhibitor activity and global fibrinolytic capacity in type 1 diabetes: evidence for normal fibrinolytic state.  J Diabetes Complications. 2006;  20 (1) 40-44
    CrossrefPubMedGoogle Scholar
  • 26 Leurs P B, van Oerle R, Hamulyak K, Wolffenbuttel B H. Tissue factor pathway inhibitor activity in patients with IDDM.  Diabetes. 1995;  44 (1) 80-84
    CrossrefPubMedGoogle Scholar
  • 27 Iorio A, Federici M O, Mourvaki E et al.. Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type 1 diabetic patients.  Thromb Haemost. 2007;  98 (3) 635-641
    PubMedGoogle Scholar
  • 28 Rigla M, Mateo J, Fontcuberta J, Souto J C, de Leiva A, Pérez A. Normalisation of tissue factor pathway inhibitor activity after glycaemic control optimisation in type 1 diabetic patients.  Thromb Haemost. 2000;  84 (2) 223-227
    PubMedGoogle Scholar
  • 29 Franklin V L, Khan F, Kennedy G, Belch J J, Greene S A. Intensive insulin therapy improves endothelial function and microvascular reactivity in young people with type 1 diabetes.  Diabetologia. 2008;  51 (2) 353-360
    CrossrefPubMedGoogle Scholar
  • 30 Schönbeck U, Libby P. CD40 signaling and plaque instability.  Circ Res. 2001;  89 (12) 1092-1103
    CrossrefPubMedGoogle Scholar
  • 31 Harding S A, Sommerfield A J, Sarma J et al.. Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus.  Atherosclerosis. 2004;  176 (2) 321-325
    CrossrefPubMedGoogle Scholar
  • 32 Varo N, Vicent D, Libby P et al.. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones.  Circulation. 2003;  107 (21) 2664-2669
    CrossrefPubMedGoogle Scholar
  • 33 Targher G, Zoppini G. Soluble CD40L in young type 1 diabetic individuals without clinical microvascular and macrovascular complications.  Diabetes Care. 2004;  27 (5) 1236-1237
    CrossrefPubMedGoogle Scholar
  • 34 Sabatier F, Darmon P, Hugel B et al.. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles.  Diabetes. 2002;  51 (9) 2840-2845
    CrossrefPubMedGoogle Scholar
  • 35 Sibal L, Aldibbiat A, Agarwal S C et al.. Circulating endothelial progenitor cells, endothelial function, carotid intima-media thickness and circulating markers of endothelial dysfunction in people with type 1 diabetes without macrovascular disease or microalbuminuria.  Diabetologia. 2009;  52 (8) 1464-1473
    CrossrefPubMedGoogle Scholar
  • 36 Goldberg R B. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications.  J Clin Endocrinol Metab. 2009;  94 (9) 3171-3182
    CrossrefPubMedGoogle Scholar
  • 37 Costacou T, Lopes-Virella M F, Zgibor J C The Pittsburgh Epidemiology of Diabetes Complications Study et al. Markers of endothelial dysfunction in the prediction of coronary artery disease in type 1 diabetes.  J Diabetes Complications. 2005;  19 (4) 183-193
    CrossrefPubMedGoogle Scholar
  • 38 Astrup A S, Tarnow L, Pietraszek L et al.. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate.  Diabetes Care. 2008;  31 (6) 1170-1176
    CrossrefPubMedGoogle Scholar
  • 39 Lin J, Glynn R J, Rifai N et al.. Inflammation and progressive nephropathy in type 1 diabetes in the diabetes control and complications trial.  Diabetes Care. 2008;  31 (12) 2338-2343
    CrossrefPubMedGoogle Scholar
  • 40 Lopes-Virella M F, Carter R E, Gilbert G E Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Cohort Study Group et al. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications.  Diabetes Care. 2008;  31 (10) 2006-2012
    CrossrefPubMedGoogle Scholar
  • 41 Soedamah-Muthu S S, Chaturvedi N, Pickup J C, Fuller J H. EURODIAB Prospective Complications Study Group . Relationship between plasma sialic acid and fibrinogen concentration and incident micro- and macrovascular complications in type 1 diabetes.  Diabetologia. 2008;  51 (3) 493-501
    CrossrefPubMedGoogle Scholar
  • 42 Brownlee M. The pathobiology of diabetic complications: a unifying mechanism.  Diabetes. 2005;  54 (6) 1615-1625
    CrossrefPubMedGoogle Scholar

Giovanni TargherM.D. 

Section of Endocrinology, Department of Medicine, University of Verona

Ospedale Civile Maggiore, Piazzale Stefani, 1, 37126 Verona, Italy

Email: giovanni.targher@univr.it